Latest Clinical News

Chemotherapy after Surgery Appears to Improve Survival in Advanced Bladder Cancer (03-31-2015)

Patients with advanced bladder cancer who receive chemotherapy after surgery to remove the bladder have better overall survival than patients who undergo surgery alone. These findings were presented at the 2015 Genitourinary Cancers Symposium on February... Continue Reading

Votrient® plus Taxol® Promising in Relapsed and Refractory Bladder Cancer (03-30-2015)

The treatment combination of Votrient® (pazopanib) plus Taxol® (paclitaxel) appears active against bladder cancer that has not responded to or come back after previous therapy. These findings were presented at the 2015 Genitourinary Cancers Symposium... Continue Reading

Cytosponge Offers Minimally Invasive Screening Option for Barrett’s Esophagus (03-26-2015)

Screening for Barrett’s esophagus with a new device called a Cytosponge is accurate compared to endoscopy but less expensive and easier on patients. These findings were reported in the journal PLoS Medicine. Barrett’s esophagus is a pre-cancerous... Continue Reading

Pacritinib May Be Effective against Myelofibrosis without Risk of Myelosuppression (03-25-2015)

The investigational agent pacritinib appears active against myelofibrosis without the risk of myelosuppression, a common side effect of many drugs used to treat myelofibrosis and other myeloproliferative neoplasms (MPN). The developers of pacritinib,... Continue Reading

Herceptin Superior to Tykerb for Treatment of HER2-positive Breast Cancer (03-24-2015)

In patients with human epidermal growth factor receptor (HER2)–positive advanced breast cancer, the combination of Herceptin® (trastuzumab) plus a taxane resulted in delayed time to cancer progression and was associated with fewer side effects than... Continue Reading

Treatment Outcomes in Stage III Colon Cancer Appear Better in Aspirin, COX-2 Inhibitor Users (03-23-2015)

According to the results of a study recently reported in the Journal of the National Cancer Institute, patients with stage III colon cancer who take aspirin or other agents that inhibit cyclooxygenase-2 near the time of adjuvant chemotherapy appear to... Continue Reading

XBiotech Launches Website and Call Center to Facilitate Recruitment for U.S. Phase III Study of Xilonix™ in Metastatic Colorectal Cancer (03-17-2015)

AUSTIN, Texas, March 12, 2015—XBiotech announced today that it has launched a website and call center to help patients with metastatic colorectal cancer learn about its U.S. Pivotal Phase III clinical trial. The Phase III study named, XilonixTM  Colorectal... Continue Reading

Sutent® Maintenance Therapy Found Active in Small Cell Lung Cancer (03-17-2015)

Doctors have reported that maintenance therapy using Sutent® (sunitinib) delays the time to cancer progression and improves survival in patients with extensive-stage small-cell lung cancer (SCLC).  These encouraging results were recently reported in... Continue Reading

Cyramza® plus Taxotere® Promising in Advanced Bladder Cancer (03-16-2015)

The treatment combination of Cyramza® (ramucirumab) plus Taxotere® (docetaxel) appears to extend progression-free survival in patients with advanced bladder cancer that has relapse after previous treatment. These findings were presented at the 2015... Continue Reading

Infection with Hepatitis C Increases Risk of Cirrhosis (03-10-2015)

People who are infected with the hepatitis C virus (HCV) have a higher risk for developing the liver disease cirrhosis, particularly within the first five years after infection. These findings were released in JAMA Internal Medicine. Cirrhosis, or late-stage... Continue Reading

Study Suggests Faslodex® Could Become New Standard First-Line Treatment of Metastatic Breast Cancer (03-9-2015)

Faslodex® (fulvestrant) at a 500-mg dose has been demonstrated to be superior to Arimidex® (anastrozole) as first-line therapy for advanced hormone receptor–positive breast cancer in the phase II FIRST study.1 Both overall survival and time to cancer... Continue Reading

The Novel Small Molecule Pictilisib May Benefit Women with Advanced Breast Cancer (03-5-2015)

The addition of the investigational drug pictilisib to Faslodex® (fulvestrant) has been demonstrated to delay the time of cancer in women with advanced or metastatic breast cancer to be positive for both estrogen receptor (ER) and progesterone receptor... Continue Reading

Next Page »